First Presentation of Data from EV-201 Pivotal
Trial of Enfortumab Vedotin in Locally Advanced or Metastatic
Urothelial Cancer Featured in an Oral Session on Monday, June
3rd
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data from
six of its proprietary programs will be presented at the upcoming
American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
taking place May 31 to June 4, 2019 in Chicago. More than 10
sessions at the meeting will feature Seattle Genetics’ approved or
investigational therapies, including an oral presentation of the
results from the enfortumab vedotin pivotal trial. The abstracts
published in advance of the ASCO meeting were made available today
on the ASCO website at www.asco.org.
“Data to be presented on our approved or investigational
targeted medicines support our efforts toward becoming a
multi-product oncology company,” said Roger Dansey, M.D., Chief
Medical Officer at Seattle Genetics. “Importantly, the oral
presentation of the results from the EV-201 pivotal trial of
enfortumab vedotin in patients with locally advanced or metastatic
urothelial cancer is our first solid tumor late-stage development
program. We are also presenting updated analyses from the ECHELON-1
and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab
vedotin) that is approved for several types of lymphomas.”
Details of the oral
presentation:
Abstract Title: EV-201: Results of Enfortumab Vedotin
Monotherapy for Locally Advanced or Metastatic Urothelial Cancer
Previously Treated with Platinum and Immune Checkpoint
Inhibitors
Abstract: #LBA4505
Presenter: Daniel P. Petrylak, M.D., Yale School of
Medicine
Date and Time: Monday, June 3, 9:24-9:36 a.m. CDT
Location: Arie Crown Theater
Details of select company- or
investigator-sponsored presentations are as follows:
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical
Hodgkin Lymphoma: Three-year Update of the ECHELON-1 Study
(Abstract #7532)
Date and Time: Monday, June 3, 8:00 a.m.-11:00 a.m.
CDT
Location: Hall A, Poster Board #286
Response to A+CHP by CD30 Expression in the ECHELON-2 Trial
(Abstract #7538)
Date and Time: Monday, June 3, 8:00 a.m.-11:00 a.m.
CDT
Location: Hall A, Poster Board #292
Response to Brentuximab Vedotin by CD30 Expression: Results
from Five Trials in PTCL, CTCL, and B-cell Lymphomas (Abstract
#7543)
Date and Time: Monday, June 3, 8:00 a.m.-11:00 a.m.
CDT
Location: Hall A, Poster Board #297
Tucatinib, Palbociclib, and Letrozole in HR+/HER2+ Metastatic
Breast Cancer: Report of Phase IB Safety Cohort (Abstract
#1029)
Date and Time: Sunday, June 2, 8:00 a.m.-11:00 a.m.
CDT
Location: Hall A, Poster Board #110
Performance of FACT-GOG-Ntx to Assess Chemotherapy-Induced
Peripheral Neuropathy (CIPN) in Pediatric Hodgkin lymphoma (HL)
Patients (Abstract #10064)
Date and Time: Saturday, June 1, 8:00 a.m.-11:00 a.m.
CDT
Location: Hall A, Poster Board #446
Details of company-sponsored trials in
progress presentations are as follows:
SGNTV-001: Open Label Phase 2 Study of Tisotumab Vedotin for
Locally Advanced or Metastatic Disease in Solid Tumors (Abstract
#TPS3160)
Date and Time: Saturday, June 1, 8:00 a.m.-11:00 a.m.
CDT
Location: Hall A, Poster Board #145a
Phase 2 Trial of Tisotumab Vedotin in Platinum-Resistant
Ovarian Cancer (innovaTV 208) (Abstract #TPS5602)
Date and Time: Saturday, June 1, 1:15 p.m.-4:15 p.m.
CDT
Location: Hall A, Poster Board #421a
SGNLVA-002: Single-Arm, Open Label Phase IB/II Study of
Ladiratuzumab Vedotin (LV) in Combination with Pembrolizumab for
First-Line Treatment of Patients with Unresectable Locally Advanced
or Metastatic Triple-Negative Breast Cancer (Abstract
#TPS1110)
Date and Time: Sunday, June 2, 8:00 a.m.-11:00 a.m.
CDT
Location: Hall A, Poster Board #186a
SGNBCMA-001: A Phase 1 Study of SEA-BCMA, a Non-Fucosylated
Monoclonal Antibody, in Subjects with Relapsed or Refractory
Multiple Myeloma (Abstract #TPS8054)
Date and Time: Monday, June 3, 8:00 a.m.-11:00 a.m.
CDT
Location: Hall A, Poster Board #379a
EV-103: Enfortumab Vedotin Plus Pembrolizumab and/or
Chemotherapy for Locally Advanced or Metastatic Urothelial Cancer
(Abstract #TPS4593)
Date and Time: Monday, June 3, 1:15 p.m.-4:15 p.m.
CDT
Location: Hall A, Poster Board #415b
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes
transformative therapies targeting cancer to make a meaningful
difference in people’s lives. ADCETRIS® (brentuximab vedotin)
utilizes the company’s industry-leading antibody-drug conjugate
(ADC) technology and is currently approved for the treatment of
multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company
has established a pipeline of novel targeted therapies at various
stages of clinical testing, including three in ongoing pivotal
trials for solid tumors. Enfortumab vedotin for metastatic
urothelial cancer and tisotumab vedotin for metastatic cervical
cancer utilize our proprietary ADC technology. Tucatinib, a small
molecule tyrosine kinase inhibitor, is in a pivotal trial for
HER2-positive metastatic breast cancer. In addition, we are
leveraging our expertise in empowered antibodies to build a
portfolio of proprietary immuno-oncology agents in clinical trials
targeting hematologic malignancies and solid tumors. The company is
headquartered in Bothell, Washington, and has a European office in
Switzerland. For more information on our robust pipeline, visit
www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the possible
utility or application of the Company’s technologies to develop
therapeutic agents, therapeutic potential of investigational
agents, and future development activities including clinical
trials. Actual results or developments may differ materially from
those projected or implied in these forward-looking statements.
Factors that may cause such a difference include the difficulty and
uncertainty of pharmaceutical product development, including the
risks that Seattle Genetics may experience delays in its planned
clinical trial initiations or otherwise experience failures or
setbacks in its preclinical and clinical development programs due
to the potential lack of efficacy or risk of adverse events or
other factors. More information about the risks and uncertainties
faced by Seattle Genetics is contained under the caption “Risk
Factors” included in the company’s Quarterly Report on Form 10-Q
for the quarter ended March 31, 2019 filed with the Securities and
Exchange Commission. Seattle Genetics disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190515005137/en/
Media:Monique Greer(425) 527-4641mgreer@seagen.com
Investors:Peggy Pinkston(425) 527-4160ppinkston@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024